Sarah Hein, March Biosciences CEO
Houston startup March Biosciences raises $28M to get CAR-T into Phase 2
A nimble Houston startup has raised a concise $28.4 million Series A to start a mid-stage trial.
The company, named March Biosciences, will enter Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
